Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

21.72 +0.06 (+0.28%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	2,202,844
Open	20.98
Bid (Size)	21.80 (100)
Ask (Size)	22.20 (200)
Prev. Close	21.66
Today's Range	20.76 - 22.14
52wk Range	13.53 - 35.25
Shares Outstanding	79,199,501
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference

November 12, 2025

From Beam Therapeutics

Via GlobeNewswire

AI Unlocks Gene-Editing Revolution: $2 Million Grant Propels Disease Cures

November 06, 2025

A groundbreaking $2 million grant from the National Institutes of Health (NIH) is set to dramatically accelerate advancements in gene-editing technology, with artificial intelligence (AI) emerging as...

Via TokenRing AI

Performance

YTD	-12.1%	-12.1%
1 Month	-20.1%	-20.1%
3 Month	+21.9%	+21.9%
6 Month	+21.4%	+21.4%
1 Year	-17.4%	-17.4%

More News

Is Beam Therapeutics Gaining or Losing Market Support? ↗

September 22, 2025

Via Benzinga

What Does the Market Think About Beam Therapeutics? ↗

August 25, 2025

Via Benzinga

Cathie Wood Goes All-In On Peter Thiel's Crypto Play Bullish With Back-To-Back Million-Dollar Buys ↗

November 04, 2025

Via Benzinga

Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates

November 04, 2025

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

November 03, 2025

From Beam Therapeutics

Via GlobeNewswire

WW International, Replimune Group, Datavault AI, GRAIL And Other Big Stocks Moving Higher On Monday ↗

October 20, 2025

Via Benzinga

Jefferies Initiates Beam Therapeutics with "Buy" Rating, Eyeing Promising Gene-Editing Pipeline and Upcoming Catalysts

October 09, 2025

Via MarketMinute

Jim Cramer Sees More Upside For Shopify, Likes CoreWeave's AI Moves ↗

October 08, 2025

Via Benzinga

Navigating the Future: Unlocking Investment Opportunities in High-Growth Sectors

October 04, 2025

Via MarketMinute

My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years ↗

September 18, 2025

Via Benzinga

Powering Progress: AI's Insatiable Energy Appetite and Biotech's Dual Dawn

August 27, 2025

Via MarketMinute

Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences

August 25, 2025

From Beam Therapeutics

Via GlobeNewswire

Pfizer's Investigational Drug Flunks Late-Stage For Sickle Cell Disease ↗

August 15, 2025

Via Benzinga

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

August 14, 2025

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)

August 05, 2025

From Beam Therapeutics

Via GlobeNewswire

10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential ↗

June 28, 2025

Via The Motley Fool

Cathie Wood's Ark Invest Continues To Offload Coinbase, Bets Big On SoFi Technologies ↗

June 27, 2025

Via Benzinga

The FDA Shake-Up Continues, And Could Impact Genetic Medicines ↗

June 20, 2025

Via Investor's Business Daily

Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst ↗

June 18, 2025

Via Benzinga

Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover ↗

June 17, 2025

Via Investor's Business Daily

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress

June 13, 2025

From Beam Therapeutics

Via GlobeNewswire

Cathie Wood's Ark Invest Continues To Offload Palantir, Loads Up On Beam Therapeutics, GitLab ↗

June 11, 2025

Via Benzinga

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

June 03, 2025

From Beam Therapeutics

Via GlobeNewswire

Frequently Asked Questions

Is Beam Therapeutics Inc. - Common Stock publicly traded?

Yes, Beam Therapeutics Inc. - Common Stock is publicly traded.

What exchange does Beam Therapeutics Inc. - Common Stock trade on?

Beam Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Beam Therapeutics Inc. - Common Stock?

The ticker symbol for Beam Therapeutics Inc. - Common Stock is BEAM on the Nasdaq Stock Market

What is the current price of Beam Therapeutics Inc. - Common Stock?

The current price of Beam Therapeutics Inc. - Common Stock is 21.72

When was Beam Therapeutics Inc. - Common Stock last traded?

The last trade of Beam Therapeutics Inc. - Common Stock was at 11/14/25 04:00 PM ET

What is the market capitalization of Beam Therapeutics Inc. - Common Stock?

The market capitalization of Beam Therapeutics Inc. - Common Stock is 1.72B

How many shares of Beam Therapeutics Inc. - Common Stock are outstanding?

Beam Therapeutics Inc. - Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.